Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide
Drug: sitagliptin

First Posted Date: 2014-03-04

Last Posted Date: 2017-05-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1059

Registration Number: NCT02077946

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: semaglutide
Drug: lisinopril
Drug: warfarin
Drug: placebo

First Posted Date: 2014-02-25

Last Posted Date: 2020-02-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 52

Registration Number: NCT02070510

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2014-02-20

Last Posted Date: 2019-10-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1631

Registration Number: NCT02066766

Locations: 🇻🇳
Novo Nordisk Investigational Site, Hanoi, Vietnam

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: placebo
Drug: semaglutide
Drug: moxifloxacin

First Posted Date: 2014-02-17

Last Posted Date: 2018-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 168

Registration Number: NCT02064348

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: semaglutide

First Posted Date: 2014-02-12

Last Posted Date: 2017-03-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT02060266

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2014-02-04

Last Posted Date: 2019-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 388

Registration Number: NCT02054897

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2014-01-14

Last Posted Date: 2017-03-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 41

Registration Number: NCT02035371

Locations: 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2014-01-14

Last Posted Date: 2020-04-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 69

Registration Number: NCT02035384

Locations: 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine
Drug: insulin aspart

First Posted Date: 2014-01-13

Last Posted Date: 2019-01-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 501

Registration Number: NCT02034513

Locations: 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2014-01-10

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT02033239

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy